Post on 27-May-2020
BIBLIOGRAPHY
1. ww w.irs.gov
2. (APBN 2004): Asia Pacific Biotech News( APBN), Vol. 8 , No. 5 ,
pp. 272.
3. Chervenak, Mathew (May - June 2005): An Emerging Biotech
Giant ? - Opportunities for Well Informed Foreign Investors
Abound in China’s Growing Biotech Sector, China Business
Review , pp. 48 - 53.
4. Palnitkar, Utkarsh (January 2005): Growth of Indian Biotech
Companies in the Context of International Biotechnology
Industry, Journal of Commercial Biotechnology, V ol. 11, No. 2,
pp. 146 -154 .
5. Mukherjee, P.N (2006): Holistic Management System for World
Class Performance and Leadership, Total Quality Management,
pp.137.
6. B, Mahadevan (September 1998): Principles of World Class
Manufacturing, The Management Accountant, pp.645 - 649.
7. Kirchhoff, Marc; Schiereck, Dirk (2011): Determinants of M&A
Success in the Pharmaceutical and Biotechnological Industry ;
The IUP Journal of Business Strategy, Vol. VIII, No. 1, pp. 25- 50.
8. Conklin, David (2011): Global Environment of Business, Investing
in New Technologies, Chapter 6, p p .ll l -136 .
9. Gobble, Mary Anne (March—April 2011): Intellectual Property
Cases Reshaping Biotech, Research and Technology Management,
pp. 5 - 6 .
10. Festel, Gunter; H. De Cleyn, Sven; Boutellier, Roman ; Braet,
Johan ( Jan - Feb 2011): Optimizing The R & D Process Using
Spin- Outs - Case Studies From The Pharmaceutical Industry,
Research and Technology Management, pp . 32 - 42.
11. Witty, Andrew (Jan 2011): New Strategies for Innovation in
Global Health - A Pharmaceutical Industry Perspective, Vol. 30,
No. 1, Health Affairs, pp. 118 -126.
12. Ahn , Mark J ; M eeks, Michael ; Davenport, Sally ; Bednarek,
Rebecca (2 0 1 0 ): Exploring Technology Agglomeration Patterns
for Multinational Pharmaceutical and Biotechnology Firms ,
Journal of Commercial Biotechnology, V ol. ,16, pp . 17 - 32 .
13. M ehra, Kavita ; Joshi, Kirti (August 2010): The Enabling Role
of the Public Sector in Innovation: A Case Study of Drug
Development in India, Innovation: Management, Policy &
Practice ,Vol. 12, Issue 2, pp . 227-237.
14. Pisoni, Alessia ; Onetti, Alberto ; Fratocchi, Luciano ; Talaia,
Marco (2 0 1 0 ): Managing R & D Activities in the Italian Biotech
Industry- A Comparison of Investments from MNCs and
Domestic Firms , The IUP Journal of Knowledge Management,
Vol. V III,N o.3, p p .3 9 -5 9 .
15. Keyhani, Salomeh ; Wang, Steven ; Hebert, P aul; Carpenter,
Daniel; Anderson, Gerard ( June 2010 ) : US Pharmaceutical
Innovation in an International Context, American Journal of
Public Health, Vol. 100, No. 6 , pp . 1075 -1085.
16. YUE , Fei- f e i; YUE ,Ying-ming (2 0 1 0 ): Study of Comparative
Advantages of Chinese and Indian Pharmaceutical Industries
Under Globalization, Management Science and Engineering, Vol.
4, No. 4, pp. 82 - 86.
17. You-Sang, KOH ( April 2010): Expanding Applications and Uses
of Biotechnology, ( Samsung Economic Research Institute) SERI
Quarterly ,pp . 40 - 48.
18. Kaufman , Michele B. ( December 2010): Management With
Specialty Pharmaceuticals Imminent for Various Conditions ,
www.formularyjournal.com , Vol. 45 , p p . 359 .
19. Kaufman , Michele B. ( December 2010): The Non - Specialty
Pharmaceutical Pipeline- What’s On the Horizon? ,
www.formularyjournal.com , Vol. 45, pp. 360.
20. Menzel, Vanessa ; Smagin , Jan ; David, Felix (2010 ): Can
Companies Profit from Greener Manufacturing? , Measuring
Business Excellence, Vol. 14, No. 2, pp. 22-31.
21. Wang ,Yow-Ming C ; Chow, Andrew T. (2 0 1 0 ): Development of
Biosimilars — Pharmacokinetic and Pharmacodynamic
Considerations , Journal of Biopharmaceutical Statistics, V o l. 20,
pp. 46-61.
22. Eriksson, Paivi; Rajamaki, Heidi (2010): Biotechnology
Marketing: Insider and Outsider Views, Journal of Commercial
Biotechnology Vol. 16, p p . 98 -108.
23. Doc. dr. sc. Bertoncelj, Andrej (2010) - Importance of Marketing
Management in the World Pharmaceutical Industry, TRZISTE ,
pp.79 - 93 Vol. XX (2008), br. 1, str. 79 - 93.
24. Quintana-garcia, Cristina; Benavides-Velasco, Carlos A. (June
2010): Accessing Technological Knowledge Through R&D
Alliances -Consequences for Radical and Incremental Innovation,
Strategy, Organization and Technology Management, pp. 1 - 37.
25. Aalbers, Rick (2010): The Role of Contracts and Trust in R&D
Alliances in the Dutch Biotech Sector, Volume 12, Issue 3,
December 2010 Innovation: Management, Policy & Practice pp.
311-329.
26. Kim, Changsu; Park, Jong-Hun (2010): The Global Research and
Development Network and its Effect on Innovation, Journal of
International Marketing, Vol. 18, No. 4, pp. 43-57.
27. Dubey, Jayashree ; Dubey, Rajesh (2010): Pharmaceutical
Innovation and Generic Challenge - Recent Trends and Causal
Factors , International Journal of Pharmaceutical and
Healthcare Marketing, Vol. 4, No. 2, pp. 175-190.
28. Ahn , Mark J ; Y ork, Anne S ; Rizova , Polly ( 2010):
Pathways to Biomedical Tipping Points: Vertical, Horizontal or
Other ?, Journal of Commercial Biotechnology, Vol .16, pp . 224 -
238.
29. Nunnally, Brian K ; McConnell, John S. ( Summer 2010): Six
Sigma in the Pharmaceutical Industry, Understanding, Reducing,
and Controlling Variation in Pharmaceuticals and Biologies, Vol.
14, N o . 3 , Open Jounal, pp. 9.
30. Maine, Elicia M.; Shapiro, Daniel M.; Vining, Aidan R. (2010):
The Role of Clustering in the Growth of New Technology-based
Firms, Small Business Economics ,Vol.34, pp.127-146.
31. Williams, David R ; Pouder, Richard W (2 0 1 0 ): R & D
Spending and Sources of Funding of Private US
Biopharmaceutical Firms Seeking to go Public, Journal of
Commercial Biotechnology ,Vol .1 6 ,2 8 4 -2 9 2 .
32. Menzel, Max-Peter ; Fornahl, Dirk ( July 2010): Cluster Life
Cycles—Dimensions and Rationales of Cluster Evolution,
Industrial and Corporate Change, Volume 19, Number 1, pp. 205-
238.
33. Wennberg, K arl; Lindqvist, GOran (2 0 1 0 ): The Effect of
Clusters on the Survival and Performance of New Firm s, Small
Business Economics, V ol. 34, pp. 221 - 241.
34. Allarakhia . D, Minna ; Kilgour, D. Marc ; Fuller, J. David(2010)
Modelling the Incentive to Participate in Open Source
Biopharmaceutical Innovation, R & D Management, V o l. 40,
No . 1, pp. 50 -66.
35. Moensted , Mette (April 2010): Networking and
Entrepreneurship in Small High-Tech European Firms - An
Empirical Study, International Journal of Management, Vol. 27 ,
No. 1, pp. 1 6 -3 1 .
36. Paruchuri, Srikanth ( January - February 2010):
Intraorganizational Networks, Interorganizational Networks ,
and the Impact of Central Inventors - A Longitudinal Study of
Pharmaceutical Firms, Organization Science, V o l. 21 , No . 1 , pp.
6 3 - 8 0 .
37. Sowlay, Mohan; Lloyd, Scott (January 2010): The Current M & A
Environment and its Strategic Implications for Emerging
Biotherapeutics Companies, Special Report - Journal of
Commercial Biotechnology, pp. 10 -1 4 .
38. Mayhew, Stephen (2010): Practical Approaches to Early Stage
Life Sciences Technology Valuations, Journal of Commercial
Biotechnology, Vol.16, pp. 120 -134 .
39. Hemphill, Thomas A. (January 2010): Pharmaceutical Patent
Expropriation and Technology Strategy: Strategic Options to
Compulsory Licensing, Technology Analysis & Strategic
Management, Vol. 22, No. 1, pp. 19 - 41.
40. Miller, J.; Johnson, A. (2010): Managing Disruptions in
Pharmaceutical Supply Chain Networks, Industrial Engineering,
pp. 1 - 6 .
41. Sowlay, Mohan; Lloyd, Scott (March 2010): Pharmaceutical
Industry - Transformation, Special Report - Journal of
Commercial Biotechnology, pp. 1 - 3 .
42. Sowlay, Mohan; Lloyd, Scott ( June 2010): Biotech in Healthcare
Business, Special Report - Journal of Commercial Biotechnology,
pp. 1 - 2 .
43. Rothaermel, Frank.T ; Hess , Andrew . M ( 2010 ) : Innovation
Strategies in Biotechnology, Special Report - Journal of Advances
in Management Research , pp. 4 - 5
44. Sowlay, Mohan; Lloyd, Scott (December 2010): M & A for
Emerging Biotherapeutics Companies, Special Report - Journal of
Commercial Biotechnology, pp. 1.
45. Khemka , Meenakshi; Gautam, Vinayshil (2010): Innovation in
the Pharmaceutical Industry - Study of Select Parameters ,
Journal of Advances in Management Research ,Vol. 7, No. 1,2011,
pp. 127 -138 .
46. Al-Laham , Andreas ; Amburgey, Terry L. (2010): Who Makes
You Central? Analyzing the Influence of International Alliance
Experience on Network Centrality of Start-up Firms,
Management, International Review V ol. 50, pp. 297-323.
47. Juan Enriquez (McKinsey Quarterly - February 23,2009): What
Matters - How Biotech Will Reshape the Global Economy, pp. 1 -
3.
48. Haseltine , William . A. ( McKinsey Quarterly - February 23,
2009): What Matters - Transforming the Material World , pp. 1-
4.
49. Stremersch , Stefan ; Van Dyck, Walter ( July 2009): Marketing
of the Life Sciences - A New Framework and Research Agenda
for a Nascent Field, Journal of Marketing V ol. 73 , pp. 4 - 30.
50. D aar, Abdallah ( McKinsey Quarterly - February 23,2009 ) :
What Matters - Big Changes, Coming Soon , pp.l.
51. Frosst, Phyllis. D. (McKinsey Quarterly - February 23,2009):
What Matters - Prognosis for Personalized Medicine, pp. 1 - 3 .
52. Woehr, Torsten ; New, Marc (2 0 0 9 ): Custom Manufacturing,
Differentiating Strategies and Success Factors for the Future,
Industry and Business , pp. 1- 4.
53. Glasberg, Glenn (2009): Japan’s Global Pharma / Biotech
Impact, The Open Business Journal - Special Report - 2009, pp. 1
54. Ahn , M ark. J .; Meeks, Michael (January 2008): Building a
Conducive Environment for Life Science - Based
Entrepreneurship and Industry Clusters , Journal of Commercial
Biotechnology, Vol.14, No.l, pp.20 - 30.
55. Ibata - Arens , Kathryn (July 2008): Comparing National
Innovation Systems in Japan and the United States - Push, Pull,
Drag, Jump Factors in the Development of New Technology, Asia
Pacific Business Review, Vol. 14, No. 3 , pp. 315-338.
56. Birch, Kean (January 2008): The Importance of Clustering in the
Biotechnology Sector, Special Report - Economic Geography,
pp. 1 -4 .
57. Birch, Kean (January 2008): An Alternative Approach to the
Cluster Theory -from the Perspective of the Biotechnology
Industry in UK, Special Report-Economic Geography, pp. 20 - 25.
58. Glick, J. Leslie ( April 2008 ) : Biotechnology Business Models
Work - Evidence from the Pharmaceutical Market Place, Journal
of Commercial Biotechnology, Vol.14, No. 2, pp.106 -1 1 7 .
59. Gottinger, Hans-Werner; Umali, Celia L. (2 0 0 8 ): Strategic
Alliances in Global Biotech Pharma Industries , The Open
Business Journal, Vol. 1, pp. 10-24.
60. Kapeleris, John; Hine, Damian (January 8,2008): Innovation and
Entrepreneurship in Biotechnology, The Open Business Journal -
Special Report, pp. 1.
61. Chiaroni, Davide ; Chiesa , Vittorio ; Frattini, Federico (2 0 0 8 ):
Patterns of Collaboration along the Bio - Pharmaceutical
Innovation Process, Journal of Business Chemistry, Vol .5, No.l,
pp. 7 - 2 2 .
62. Berthon , Pierre ; Pitt, Leyland ; N el, Deon ; Salehi - Sangani,
Esm ail; Engstrom, Anne ( July 2008): The Biotechnology and
Marketing Interface - Functional Integration Using Mechanistic
and Holographic Response to Environmental Turbulence, Journal
of Commercial Biotechnology, Vol.14, No.3, pp.213 - 224.
63. Rajamaki, Heidi ( July 2008): Anticipating and Managing the
Challenges of Biotechnology Marketing, Journal of Commercial
Biotechnology , Vol.14, No.3, pp . 225-231 .
64. Liang, Shing - Ko ; Jiang, Jyun - Lin ; L a i, Chia - Te (March
2008): Effects of Integrative Strategies on the Production
Efficiency of Biotechnology Firms - A Data Development Analysis
, International Journal of Management, Vol.25, No.l, pp.140 -
148
65. Rao, Raghunath Singh; Chandy, Rajesh. K; Prabhu , Jaideep . C
(July 2008): The Fruits of Legitimacy - Why Some New Ventures
Gain More from Innovations Than Others, Journal of Marketing
, Vol. 7 2 ,pp. 5 8 -7 5 .
66. Vanderbyl, Sandra ; Kobelak, Sherry ( February 2007 ) : Critical
Success Actors for Biotechnology Industry in Canada, Journal of
Commercial Biotechnology ,Vol .13, No. 2, pp.68 - 77.
67. Brannback, Malin ; Carsrud , Alan ; Renko, Maija (March
2007): Exploring the Born Global Concept in the Biotechnology
Context, Journal of Enterprising Culture, Vol. 15, No.l, pp.79 -
100.
68. Kind, Sonja; Knyphausen - Aufsef), Dodo Zu (April 2007):
Business Development - What is “Business Development?” The
Case of Biotechnology, SBR 59, pp.176 -199 .
69. Frahm, Jennifer; Ireland, David .C ; Hine, Damian (May 2007):
Constructing a Processual Model of Communication in New
Product Development from a Multiple Case Study of Biotech
SMEs, Journal of Commercial Biotechnology ,V ol. 13, No. 3, pp.
151-161.
70. Cader, Yoosuf (May 2007): Knowledge Management and
Knowledge - Based Marketing, Journal of Business chemistry,
Vol. 4, Issue 2, pp. 46 - 58.
71. Coman , A ; Ronen , B ( February 2007 ) : Managing Strategic
and Tactical Constraints in the Hi - Tech Industry, International
Journal of Production Research, Vol. 45 , N o . 4 , pp. 779 - 788.
72. Fontes, Margarida (May 2007): Technological Entrepreneurship
and Capability Building in Biotechnology, Special Report -
Technology Analysis and Strategic Management, pp.l -15.
73. Wolson, Rosemary. A (2007): The Role of Technology Transfer
Offices in Building the South African Biotechnology Sector - An
Assessment of Policies , Practices, and Impact, Journal of
Technology Transfer, Vol.32, pp.343 - 365.
74. ThorsteinsdOttir, Halla (September 2007) : The Role of the
Health System in Health Biotechnology in Developing Countries ,
Technology Analysis and Strategic Management, Vol.19, No. 5,
pp.659 - 675.
75. Mittra , James (May 2007): Life Science Innovation and the
Restructuring of the Pharmaceutical Industry - Merger,
Acquisitions and Strategic Alliance Behavior of Large Firms,
Technology Analysis and Strategic Management, Vol.19, No.3, pp.
279-301 .
76. Kleyn, Dominique; Kitney, Richard; Atun, Rifat. A (June 2007):
Partnership and Innovation in the Life Sciences , International
Journal of Innovation Management, Vol. 11, No.2, pp.323 - 347.
77. Lane, Christel; Probert, Jocelyn (February 2007) : The External
Sourcing of Technological Knowledge by US Pharmaceutical
Companies - Strategic Goals and Inter - Organizational
Relationships , Industry and Innovation ,V ol. 14, N o .l , pp. 5 -
25.
78. Sen , Sharmistha Bagchi (July 2007): Strategic Considerations
for Innovation and Commercialization in the US Biotechnology
Sector, European Planning Studies, Vol.l5,No.6, pp.753 - 766.
79. Couillard , Denis (July / August 2007): Why Creating a Learning
Organization Leads the High Tech Firm to Succeed, Ivey Business
Journal -London, pp.l - 7.
80. TO dt, Oliver ; Gutierrez - Gracia, Antonio ; Fernandez de
Lucio , Ignacio ; Castro - Martinez, Elena (2007): The Regional
Dimension of Innovation and the Globalization of Science -The
Case of Biotechnology in a Peripheral Region of the European
Union , R & D Management, V ol. 37, No.l, pp.65 - 74.
81. Rothman , Harry ; K raft, Alison (January 2006): Downstream
and into Deep Biology- Evolving Business Models in “ Top Tier “
Genomics Companies, Journal of Commercial Biotechnology,
Vol.12, No.2, pp. 86 - 98
82. W olff, M.F. (January - February - 2006) : Views and News of
the Current Research - Technology Management Scene -
Perspectives - South East Asia Drives for Biotech Supremacy,
Research and Technology Management, pp . 2 - 4.
83. Traore, Namatie (March 2006): Networks and Rapid
Technological Change - Novel Evidence from the Canadian
Biotechnology Industry ,Industry and Innovation , Vol .13, No.l,
pp. 41 - 68.
84. Okamura, Koichiro; Vonortas, Nicholas.S (December 2006):
Alliance and Knowledge Networks, Technology Analysis and
Strategic Management, Vol. 18, No . 5 , pp. 535 - 560.
85. Baskaran , Angathevar; Pancholi, Jatin ; Ghaffari, Firoozeh
( Summer 2006): A Period Study of Short - Term Performance
Pressures : Case of the British Biotechnology Industry, The
Business Review - Cambridge, Vol. 5,No.2, pp.327 - 332.
86. Churchill, Clare. A . C .; Belsey, Mark . J (April 2006):
Autoimmune and Inflammatory Disorder Biologicals Will Power
Biotech Market Growth Through to 2010, Journal of Commercial
Biotechnology, Vol. 12, N o . 3, pp. 237 - 241.
87. Quezada , Fernando ( April 2006): Commercial Biotechnology in
Latin America - Current Opportunities and Challenges, Journal
of Commercial Biotechnology, Vol.12, No.3, pp.192 -199 .
88. Nosella, Anna ; Petroni, Giorgio ; Verbano , Chiara ( May 2006)
: How Do Italian Biotechnology Start - Ups Survive ?,Journal of
Business Chemistry, Vol.3, Issue No.2, pp.7 -1 4 .
89. Ramirez, Paulina ( May 2006 ) : The Globalization of Research
in the Pharmaceutical Industry - A Case of Uneven Development,
Technology Analysis and Strategic Management, Vol.18, No.2,
pp.143 -1 6 7 .
90. Maurer, Indre ; Ebers, M ark; ( June 2006): Dynamics of Social
Capital and their Performance Implications- Lessons from
Biotechnology Start - U ps, Administrative Science Quarterly (
A SQ ) ,VoL51, pp. 262 - 292.
91. Pijpers , Fleur; Belsey, Mark . J . ( July 2006 ) : Cancer
Remains the Dominant Disease Target for Biotech Through to
2010 , Journal of Commercial Biotechnology, Vol. 12, No.4, pp .
294-298 .
92. Johnston , Kate ; Henry, Colette ; Gillespie, Simon ( August 8 ,
2006): Encouraging R & D in Ireland’s Biotechnology
Enterprises, The Irish Journal of Management, Vol .9, pp.207 -
228.
93. Sedgley , Mike ( September 2006): Pharmaceutical and
Government Policy - The State Giveth and the State Taketh Away
- Supporting the Research Based Pharmaceutical Industry in
Europe and the UK, Institute of Economic Affairs (IEA), pp. 39 -
47.
94. Pisano , Gary . P. (October 2006): Can Science Be a Business? -
Lessons from Biotech, Harvard Business Review, pp. 114 -125 .
95. W ong, Joseph ( October 2006): Technovation in Taiwan :
Implications for Industrial Governance, International Journal of
Policy, Administration , and Institutions,Vol.19, No.4, pp . 651 -
672.
96. Mytelka, Lynn. K. ( December 2006) :Pathways and Policies to (
B io) Pharmaceutical Innovation System in Developing Countries
,Industry and Innovation, Vol.13, No.4, pp.415 - 435.
97. Bower, Jane. D ; Sulej, Julian ( December 2006): Social and
Intellectual Capital Formation in Leading Indian Pharmaceutical
Companies, International Journal of Innovation Management,
Vol.10, No.4, pp. 407-423.
98. Hendry, Chris ; Brown, James (2 0 0 6 ): Organizational
Networking in UK Biotechnology Clusters , British Journal of
Management, Vol.17, pp.55 - 73.
99. Fetterhoff, Terry. J .; Voelkel, Dirk ( 2006): Managing Open
Innovation in Biotechnology, Research and Technology
Management, pp. 14 - 18.
100. Hagedoorn , John ; Roijakkers, Nadine; Kranenburg, Hans
Van ( 2006): Inter - Firm R & D Networks - The Importance
of Strategic Network Capabilities for High-Tech Partnership
Formation, British Journal of Management, Vol. 17 , p p . 39 - 53.
101. Khilji, Shaista. E .; Mroczkowski, Tomasz ; Bernstein, Boaz (
2006): From Invention To Innovation - Toward Developing an
Integrated Innovation Model for Biotech Firms , The Journal of
Product Innovation Management ( J Prod Innov Manag) , Vol.
23 ,pp. 528 - 540.
102. Englande, A. J . ; J in , Guang (2 0 0 6 ): Application of
Biotechnology in Waste Management for Sustainable
Development - An Overview, International Journal of
Management and Environmental Quality, Vol.17, No.4, pp. 467 -
477.
103. Burow, Scott. A.; Berghammer, Joseph . J. ( August 2006):
Patent Protection in the Biotechnology Industry - A Unique
Approach to Obtaining Fast Patent Rights,Intellectual Property
and Technology Law Journal, V ol. 18, No. 8, pp. 18 - 20.
104. Attridge , Jim ( September 2006): Pharmaceuticals and
Government Policy - Equity of Access to Innovative Medicines -
Mission Impossible ?, Institute of Economic Affairs ( IEA ) ,pp.l7
-23
105. Lim , L isa. P . L .; Garnsey, Elizabeth ; Gregory, Mike (
2006): Product and Process Innovation in Biopharmaceuticals -
A New Perspective on Development, R & D Management, Vol .36,
No.l, pp . 27 -3 6 .
106. Vazquez, Emma Gutierrez de Mesa ; Martin, Juan Angel
Jimenez ; Mascarenas , Juan ( April 2006): Strategic Alliances
as a Mechanism for Wealth Creation in the Biopharmaceutical
Industry - an Empirical Analysis of the Spanish C ase, Journal
of Commercial Biotechnology, V ol. 12 , No. 3 , pp .229 - 236.
107. Gollin, Michael; Jack, Eva ; Chase, Terry; Soriano, Jesus;
Smith, Robert ( April 2006): Winning the Game - Public Funds
for Biotech Companies, Journal of Commercial Biotechnology,
Vol. 12, No.3, pp. 220-228.
108. Pavlou , Alex ; Belsey , Mark ( January 2005) : Key Financial
Trends that Shape Biotechnology Business Growth , Journal of
Commercial Biotechnology, V ol. 11, No. 2 , pp. 171 -1 7 5 .
109. Joshi, Sanjaya.N (June 2005): Creating a Biotechnology Hub -
Lessons from the BioForest, IIMB Management Review, pp. 50 -
58.
110. Blau, John (November - December 2005): German Biotech -
Coming Back, Research and Technology Management, pp. 4- 5 .
111. Kowalski, Thomas . T ; Fekete, Pamela ; Yvon, Anne - Marie.
C (April 2005): The Quest for Generic Biotechnology
Pharmaceuticals in the USA, Journal of Commercial
Biotechnology, Vol .11, No.3, pp. 271 -274 .
112. Bower, Jane. D (June 2005): From the “Rhetoric of Hope” to
the “Patient - Active Paradigm” - Strategic Positioning of
Pharmaceutical and Biotechnology Companies, Technology
Analysis and Strategic Management, Vol. 17, No. 2, pp . 183 -
204.
113. Ghadar, Fariborz ; Spindler, Heather (March - April 2005)
Global Tectonics - Part I - The Growth of Biotechnology,
Industrial Management, p p . 19 - 23
114. Schweizer, Lars (2 0 0 5 ): Organizational Integration of
Acquired Biotechnology Companies into Pharmaceutical
Companies - The Need for a Hybrid Approach, Academy of
Management Journal ,Vol.48, No.6, pp .1051-1074.
115. Laroia , Gaurav ; Krishnan, Shiv ( September - October -
2005 ) : Managing Drug Discovery Alliances for Success -
Applying the Lessons Learned from Aventis‘s Alliance
Experience Could Improve the Productivity of Such Alliances,
Research and Technology Management, pp. 42 - 50.
116. Salman, Nader; Saives , Anne - Laure (2 0 0 5 ): Indirect
Networks - An Intangible Resource for Biotechnology Innovation,
R & D Management, V ol. 35, No.2, pp. 203 - 305.
117. Baker, Ann; Gill, Jasween (October 2005): Rethinking
Innovation in Pharmaceutical R & D , Journal of Commercial
Biotechnology, Vol. 12, No. 1, pp. 45 - 49.
118. Termeer, Henri. A (July 25,2005): The Alchemy of
Biotechnology - Third Edition, Boston Globe, Boston,
Massachusetts, pp. 267 - 268.
119. Gertler, M. S; Levitte, Y. M. (December 2005): Local Nodes in
Global Networks; The Geography of Knowledge Flows in
Biotechnology Innovation, Industry and Innovation, Vol. 12, No. 4,
pp.487 - 507.
120. Nicholson , Sean ; M. Danzon, Patricia ; McCullough, Jeffery (
July 2005 ) : Biotech - Pharmaceutical Alliances as a Signal of
Asset and Firm Quality, The Journal of Business, V o l. 78, No. 4,
pp. 1433 -1464.
121. Fontes, Margarida (September 2005): Distant Networking -
The Knowledge Acquisition Strategies of “Out - Cluster
“Biotechnology Firms, Special Report - European Planning
Studies, pp. 1-21
122. Fontes , Margarida ( December 2005): Building Capabilities
in Biotechnology, Special Report - European Planning Studies, pp.
1- 11.
123. Filho, Lelio Felows ; Maria dos Santos , D alci; Coelho, Gilda
M assari; Santos , Marcio de Miranda ( September 2005): Future
Studies in Brazil: Centro de Gestao e Estudos Estrategicos
(CGEE) Approach for Biotechnology and Nanotechnology,
Journal of Business Chemistry, V ol. 2 , Issue 3 , pp.126 -1 3 7
124. Williams, Alan (April 2005): Corporate Development in
Biotech in 2005, Journal of Commercial Biotechnology, Vol. 11,
No. 3, pp. 239-248 .
125. Parayil, Govindan (Winter 2005): From “Silicon Island “ to “
Biopolis of Asia “ - Innovation Policy and Shifting Competitive
Strategy in Singapore , California Management Review ( CM R) ,
V ol. 47, No. 2, pp. 5 0 - 7
126. Anonymous (March - April 2005): EU Scoreboard Reveals
Need for Industrial R & D Champs- EU Industrial R & D
Investment Scoreboard, Research and Technology Management,
pp. 5 - 8 .
127. Lynskey, Michael. J. (July 2005): Moving Beyond Metaphors -
University - Industry Collaboration in Biotechnology, Journal of
Commercial Biotechnology, V ol. 11, No. 4, pp. 301 -304 .
128. Piachaud , Bianca ( May - June 2005): Outsourcing
Technology,Research and Technology Management, pp . 40 - 46.
129. Garcia; Quintana ; Velasco , Benavides ( November 15,2005)
: Agglomeration Economies and Vertical Alliances : The Route to
Product Innovation in Biotechnology Firms, International
Journal of Production Research, V o l. 43, No. 22, pp. 4853-4873.
130. Sell, Christopher (January 28,2005): Applied Technologies for
Production Engineers; Production Engineering, Industrial Biotech
pp. 31-33.
131. Howell, Julian ( July 2004): The Why and How of US
Market Entry : A Qualitative Study of Non - US Pharmaceutical
Companies, International Journal of Medical Marketing, V ol. 4,
No. 3, pp. 235-250 .
132. Finegold , David ; W ong, Poh - Kam Wong ; Cheah , Tsui -
Chern ( October 2004): Adapting a Foreign Direct Investment
Strategy to the Knowledge Economy - The Case of Singapore’s
Emerging Biotechnology Cluster, European Planning Studies ,
V ol. 12 ,No. 7 ,p p .921-941.
133. Philip Cooke (May 2004) :Life Sciences Clusters and Regional
Science Policy, Urban Studies, Vol. 41, Nos. 5 & 6 , pp. 1113 -1131
134. Lawton Smith, Helen (October 2004): The Biotechnology
Industry in Oxfordshire - Enterprises and Innovation, European
Planning Studies, Vol. 12, No. 7, pp. 985 -1001.
135. Kean, Marcia. A(May 2004):Biotech and the Pharmaceutical
Industry - Back to the Future, The Observer , No . 243, pp. 21 -
22.
136. Kak, Anjana (2004): Strategic Management, Core
Competence and Flexibility - Learning Issues for Select
Pharmaceutical Organizations, Global Journal of Flexible Systems
Management, Vol. 5, No. 4, pp 1-15.
137. Asia Pacific Biotech News ( APBN 2004): How Biotechnology
Can Improve Global Health - Global Development ,Vol.8 , No.6
pp. 3 40 -342
138. P. L .Lim, Lisa; J. Gregory, Michael (June 2004): Singapore’s
Biomedical Science Sector Development Strategy; Is it
Sustainable? , Journal of Commercial Biotechnology; Vol. 10, No.
4, pp.352 - 362.
139. Anonymous (October 2004): Biotechnology Industry Finds
Fertile Ground in The Netherlands, Biopharm International, V ol.
17, No. 10, pp. 62 - 68.
140. Mamidi, Pavan ( June 2004 ) : Biotechnology and Business,
IIMB Management Review, pp. 49 - 62.
141. Anonymous (September - October 2004): Tech Talk -R & D ,
Research and Technology Management, pp. 5 - 6 .
142. Thumm, Nikolaus (December 2004): Strategic Patenting in
Biotechnology, Technology Analysis and Strategic Management,
V ol. 16, No. 4 ,5 2 9 -5 3 8 .
143. Rzakhanou , Zaur (December 2004): Innovation , Product
Development, and Market Value : Evidence from the
Biotechnology Industry, Economic Innovation New Technology,
V ol. 13,No. 8, pp. 747-760.
144. Hennessey, Raymond (January 8 ,2004): Deal and deal
makers - IPO‘s for Biotech Face Skepticism After a Rough 2003 ,
The Wall Street Journal - Eastern Edition, - New York -NY,
p p .1 -2
145. LOffler, Alicia (2004): The Evolving Role of Marketing in
Biotechnology, Biotech Ventures, pp. 1- 4.
146. L6ffler, Alicia (2004): Optimizing the Marketing Function,
The Open Business Journal- Special Reports -2004, pp. 11-15.
147. Han, Dr. Yongliang “Staanley “(September 2004): Is
Technology Pre - emption a Motive for R & D Alliances?
Evidence from the Biotechnology Industry, Journal of American
Academy of Business - Cambridge, V ol. 5, Nos. 1 & 2, pp.215 -
219.
148. Prahalad , C.K ; Ramaswamy , Venkatram ( 2004 ) : The
Future of Competition - Co - Creating Unique Value with
Customers , HBR School Press , Boston , MA.
149. Chiesa, Vittorio; Toletti, Giovanni (March 2004): Network of
Collaborations for Innovation- The Case of Biotechnology,
Technology Analysis and Strategic Management, Vol. 16, No. 1 ,
pp. 73 - 96.
150. Acemoglu, Daron ; Linn, Joshua ( August 2004): Market Size
in Innovation - Theory and Evidence from the Pharmaceutical
Industry, The Quarterly Journal of Economics ,pp. 1049 -1090.
151. Lehrer, M ark; Asakawa, Kazuhiro (Spring 2004): Pushing
Scientists into the Market Place : Promoting Science
Entrepreneurship , CM R, V ol. 46, No. 3, pp. 55 - 76.
152. Asia Pacific Biotech News (2 0 0 4 ): Singapore’s Conducive
Biomedical Sciences Environment, V ol. 8 , No . 5 , pp. 272 - 273.
153. Leibovitz, Joseph (May 2004): Embryonic Knowledge - based
Clusters and Cities: The Case of Biotechnology in Scotland, Urban
Studies, Vol. 41 , Nos. 5 & 6, pp. 1133 -1155.
154. M uller, Christian ; Fujiwara, Takao ; Herstatt, Cornelius
( 2004): Sources of Bio- entrepreneurship - The Cases of
Germany and Japan , Journal of Small Business Management,
V ol. 42, No. 1, pp.93 - 101.
155. De Rond, M; Bouchikhi, Hamid (2004): Strategic Alliances,
Organization Science, Vol. 15, No. 1, pp. 68.
156. McCarthy, Robert. C (March - April 2003): Linking
Technology Change to Business Needs, Research and Technology
Management, pp. 47 - 52
157. Howard, Nigel (October 28 ,2003): Exploring Strategy
Through Outsourcing in the Biotech Industry, The Open Business
Journal Special Reports - 2003, pp. 1.
158. Varaiya , N ikhil. P .; Evans , Anne. G . ( Fall 2003):
Assessment of a Biotechnology Market Opportunity,
Entrepreneurship Theory and Practice,pp. 87 - 105.
159. K, Balaji ( 2003 ) : Competitive Positioning Strategies for
Australian Biotechnology Companies, Global Biotechnology
Market Overview and Opportunity Analysis, 2003, pp.4 -7.
160. Cooper, John (March 2003): The Biotech Boom Builders,
CMA Management, Vol. 77, No. 1, pp. 24 -29.
161. Asia Pacific Biotech News (APBN 2003): Vol .7, No.10, pp.512.
162. Asia Pacific Biotech News ( APBN 2003): Vol .7 , No.15 ,
pp.913.
163. Frost and Sullivan ( APBN 2003) : Special report - Asia
Pacific Biotech News APBN (2003 ) , pp.l
164. Anonymous (December 2003): Bio- information -
Biotechnology R & D , The Observer, No. 240 -241, pp.
165. Anonymous (December 2003): Bitter Pill - Higher
Pharmaceutical Spending, The Observer, No. 240 -241, pp. 85.
166. Quere, Michel ( September 2003): Knowledge Dynamics -
Biotechnology ‘s Incursion into the Pharmaceutical Industry,
Special Report - Industry and Innovation , pp.l - 25.
167. Quere, Michel (April 2003): Current Development of Bio -
Informatics, Special Report - Industry and Innovation, pp. 1-15.
168. Cooke, Philip ( October 2003): The Evolution of
Biotechnology in Three Continents : Schumpeterian or
Penrosian, European Planning Studies, V ol. 11, No. 7 , p p . 757 -
763.
169. Kermani, Faiz ; Bonacossa, Pietra ( December - 2003):
Current and Future Prospects for the Global Biotechnology
Industry, Journal of Commercial Biotechnology ,Vol.l0, No.2 ,
pp.154 -164 .
170. Pavlou, Alex. K. (January 2003): Biotechnology Industry -
Insights from Europe, Journal of Commercial Biotechnology,
Special Report - pp. 1-11.
171. Pavlou, Alex. P. (December 2003): Leading Biotechnology
Players 2002: 2008 - Key Products - Indications and Technologies,
Journal of Commercial Biotechnology; Vol. 10, No. 2, pp. 167 -
176.
172. Jen Fr0slev Christensen ( September 2003 ) : The Industrial
Dynamics of Biotechnology - New Insights and New Agendas —
Introduction , Industry and Innovation , Vol.10, No.3, pp. 223 -
230.
173. Frost & Sullivan (APBN 2003): Asia Pacific Biotech news,
Global Biotechnology Market Overview, Vol. 7, No. 12, pp.704 -
707.
174. K ato, Makino ; Macer, Darryl ( January 2003): How
Biotechnology Companies Respond to Bioethical Issues, Journal
of Commercial Biotechnology, V ol. 19, No. 2, pp. 153 -162 .
175. Mcgarvey, Robert ( May 2003 ) : Biotech Advances -
Transforming Our Lives With New Drugs , Better Crops, Even
Personalized Medicines, HBR Publication Corporation, p p . 51 -
53
176. Newton, Alastair (November 2003): Europe4s Biotechnology
Hub - The UK, Biopharm International, Vol. 16, No. 11, pp. 52 -
58.
177. Carbone , June ( July 2003 ): Ethics , Patents and the
Sustainability of the Biotech Business M odel, International
Review of Law Computers and Technology, V o l. 17, No. 2, pp.
203-218 .
178. Lloyd, Wayne (January 2003): A New Era of Networking,
Journal of Commercial Biotechnology, Vol. 9, No. 2, pp. 97 - 98.
179. Weinstein, Olivier; Orsi, Fabienne; Coriat, Benjamin
(September 2003): Does Biotech Reflect a New Science - based
Innovation Regime? , Industry and Innovation, Vol. 10, No. 3, pp.
231-253.
180. Pavlou, A lex. K . ( June 2003) .'Trends in Biotherapeutics,
Journal of Commercial Biotechnology , Vol 9, No.4, pp.358 - 363.
181. Baker, Ann ( June 2003 ) : Opinion Piece - Biotechnology -
Growth - Innovation Paradox and the New Model for Success ,
Journal of Commercial Biotechnology, V ol. 9, No . 4, pp. 286 -
288.
182. Sorescu, Alina. B; Chandy, Rajesh. K; Prabhu, Jaideep. C
(October 2003): Sources and Financial Consequences of Radical
Innovation - Insights from Pharmaceuticals, Journal of
Marketing, Vol. 67, pp. 82 - 102
183. Anonymous ( 2003): New Drug Development - Increasing
Costs , Mckinsey Quarterly , pp.4.
184. Asia Pacific Biotech News ( APBN 2003): General
Information & Statistics - India - Southern India Cities Poised for
Fast Biotech Growth, pp.53.
185. Anonymous ( May 24 ,2 0 0 3 ): The Insider - Biobusiness
Trends - Europe’s Biotech Woes ,The New Scientist - London ,Vol
. 178 , Issue 2396 , pp . 61 - 62
186. Grupp, Robert. W ; Gaines - Ross , Leslie ( September 2002)
: Reputation Management in the Biotechnology Industry ,
Journal of Commercial Biotechnology, V o l. 9, No.l, pp. 17 - 26.
187. Zollo , Maurizio ; Rever, Jeffery; Singh , Harbir (
November - December 2002): Inter - Organization Routines
and Performance in Strategic Alliances, Organisation Science , Vol
. 13, No. 6, pp. 701 - 713.
188. D ing, Ming ; Eliashberg, Jehoshua ( March 2002):
Structuring the New Product Development ( NPD ) Pipeline,
Management Science, V ol. 48 , No. 3 ,pp. 343 - 363
189. Muller, Christian (2002): Strategic Management - A Tool for
Growth in the Biotechnology Sector, Journal of Commercial
Biotechnology, Vol. 8, No. 3 , pp. 226 - 234.
190. LOffler, Alicia (2002 ) - Trends in Biotechnology -
Implications for the Pharmaceutical Industry, International
Journal of Medical Marketing, V ol. 2 , No. 4 , pp. 345 - 348
191. S, Garrett ( June 2002) : A Framework for Effective Market
Planning and Analysis - Eleven Steps to successful Market
Planning, Pharmaceutical Executive’s Successful Product
Management Supplement, pp . 6-18.
192. Anonymous (2002): Future of Biotechnology - A Mckinsey
and Lehman Brothers Study, Mckinsey Quarterly , pp.l.
193. Fisken , Jane ; Rutherford , Jan ( 2002 ) : Business Models
and Investment Trends in the Biotechnology Industry in Europe,
Journal of Commercial Biotechnology, V o l. 8, No. 3, pp. 191 -
199.
194. Coile, Russell. C ( November / December 2001): Impact of
The “ New Science “ of Genomics - Future Trends , Journal of
Healthcare Management, V ol. 46, No. 6, pp. 365 - 368.
195. Steensma, H. Kevin ; Corley, G. Kevin ( April 2001):
Organizational Context as a Moderator of Theories on Firm
Boundaries for Technology Sourcing, Academy of Management
Journal, V o l. 44, No. 2, pp .271 - 291.
196. Niosi, Jorge; Bas, Thomas. G ( August / September 2001):
The Competencies of Region - Canada’s Clusters in
Biotechnology, Small Business Economics , V o l. 17, Nos. 1 & 2,
pp. 31 - 41.
197. Orsenigo , Luigi ( August / September 2001 ) : The ( Failed)
Development of a Biotechnology Cluster - The Case of Lombardy
, Small Business Economics , V ol. 17 , Nos. 1 & 2 , pp . 77 - 92.
198. Weisenfeld, Ursula ; Reeves , James . C ; Hunck - Meiswinkel,
Astrid ( 2001): Technology Management and Collaboration
Profile - Virtual Companies and Industrial Platforms in the High
- Tech Biotechnology Industries, R & D Management, V ol. 31 ,
No . 1 , pp. 91 -100 .
199. Ostergard , Robert. L ; Tubin, Matthew , J r ; Altman , Jordan
( 2001 ): Stealing from the Past - Globalization , Strategic
Formation and the use of Indigenous Intellectual Property in the
Biotechnology Industry ,Third World Quarterly, Vol. 22, No.4 ,
p p .643 - 656.
200. Feldmann , Maryann . P.; Ronzio , Cynthia. R (2 0 0 1 ):
Closing the Innovative Loop : Moving from the Laboratory to the
Shop Floor in Biotechnology Manufacturing, Entrepreneurship
and Regional Development, V ol. 13, pp. 1-16
201. North, Nigel (March - April 2000): Implementation of
Analytical Technologies in a Pharmaceutical Development
Organization - Looking into the Next Millennium, Journal of
Automated Methods and Management in Chemistry, Vol. 22, No.
2, pp. 41 - 45.
202. Madhok, Anoop ; Osegowitsch , Thomas ( Second Quarter
2000): The International Biotechnology Industry - A Dynamic
Capabilities Perspective, Journal of International Business
Studies , V ol. 31, No. 2, pp. 325 - 335.
203. Mason, James (August 1999): Challenges to the Economic
Evaluation of New Biotechnological Interventions in Healthcare,
Pharmocoeconomics, Vol. 16, No. 2, pp.119 -125 .
204. Himmelsbach, Vawn (June 4,1999): Canada Leads R & D
Efforts in Biotechnology, Computing Canada, Vol.25., No. 22, pp.
2 5 -2 6 .
205. Anonymous (March 1999): How Big is Biotech? , Organization
for Economic Cooperation and Development - The OECD
Observer, March 1999, No. 216, pp. 18 -19.
206. Powell, Walter. W (Spring 1998): Learning from
Collaborations - Knowledge and Networks in the Biotechnology
and Pharmaceutical Industries, California Management Review,
Vol. 40, No. 3, pp. 228 - 240.
207. Dyers , J.H; Singh, H (1998): The Relational View -
Cooperative Strategy and Sources of Inter - organizational
Competitive Advantage, Academy of Management Review, V ol.
23 , No. 4 , pp. 660 - 679.
208. Burgers , Willem . P ; Cromartie, Jane. S ; Davis , Ronnie. J
(1998): Cooperative Competition in Global Industries - The
Strategic Dimension, The International Trade Journal, V o l. X II,
No . 4 , pp . 421 - 445.
209. Pahud de Mortanges , Charles ; Rietbroek, Jan - Willem;
Johns , Cort Maclean (1997): Marketing Pharmaceuticals in
Japan - Background and the Experience of US Firms , European
Journal of Marketing, V ol. 31 , No . 8, pp. 561 -582 .
210. Teecee, D . J ; Pisano . G ; Shuen , A (1997): Dynamic
Capabilities and Strategic Management, Strategic Management
Journal, V ol. 18 , pp . 509 - 533.
211. Oliver, Amalya .L ; Lieberkind , Julia Porter (Winter 1997):
Three Levels of Networking for Sourcing Intellectual Capital in
Biotechnology, International Studies of Management and
Organization, V ol. 27 , No . 4 , p p . 76 -103 .
212. Schmidt, Robert. L (April 1996): A Stochastic Optimization
Model to Improve Production Planning and R & D Resource
Allocation in Biopharmaceutical Production Processes,
Management Science, Vol. 4 2, No. 4, pp. 6 0 3 - 6 1 7.
213. Audretsch , David . B ; Stephan . E ., Paula (June 1996):
Company - Scientist Locational L inks-T he Case of
Biotechnology, The American Economic Review , V ol. 86 , No . 3
, pp . 641 - 652.
214. Burgelman , Robert. A ; Grove, Andrew. S (Winter 1996):
Strategic Dissonance, California Management Review ( CMR
reprint series), V o l . 38, No.2, p p . 3 - 23.
215. M oller, K (1995): Business Marketing - An Interactionand
Networking Perspective, Kluwer Academy Publishers, Boston ,
MA.
216. Yeoh , Poh - Lin (1994): Speed to Global Markets - An
Empirical Prediction of New Product Success in the Ethical
Pharmaceutical Industry, European Journal of Marketing,Vol.
28, No. 11, pp. 2 9 -4 9 .
217. Solt, Michael. E (Summer 1993): SWORD Financing of
Innovation in the Biotechnology Industry, Financial Management,
pp. 173 -187.
218. Barney, Jay (1991): Firm Resources and Sustained
Competitive Advantage, Journal of Management, V o l . 7, No. 1,
pp. 99 -120 .
219. Fildes, Robert. A (Spring 1990): Strategic Challenges in
Commercializing Biotechnology, California Management Review
(CMR), pp. 63 - 72.
220. Arora, Ashish ; Gambardella, Alfonso ( June 1990):
Complementarity and External Linkages - The Strategies of Large
Firms in Biotechnology , The Journal of Industrial Economics,
Volume XXXVIII, No. 4 , p p . 361 - 379.
QUESTIONNAIRE FOR COMPANIES
NAME OF THE COMPANY
ADDRESS:
ANNUAL TURNOVER: INR________ MILLION
NAME OF THE INTERVIEWEE:
DESIGNATION:
1. Does your company have a vision statement?
Yes____No____
2. If yes, what is your company’s vision statement?
3. Does your company have a mission statement?
Yes___No
5 If yes, what is your company’s mission statement?
6 According to you, how does this vision and mission statement help your company achieve its’ objectives?
7 Do you have a defined customer segment(s)?
Yes__________No__________
8 If yes, could you describe the segment(s)?
9 How do you assess user needs?
Market Research__________
Employees’ Feedback____________
Dealers’ / Distributors’ Feedback_________________
Customers’ Feedback_______________
Suggestions for Improvement from Stakeholders, If Any______
10 What is your procedure for generating ideas for improvement / new ideas for product / process?
12 Do you conduct a formal SWOT analysis?
Yes__________No_______ ^
13 Who are your major competitors?
14 Do you have a formal competitor analysis?
Yes__________No__________
15 If yes, how often do you analyze competitors?
16 What opportunities and threats do you perceive for your products?
In One Year___________
In Three Years______________
In Five Years
18 Could you briefly explain your procedure for strategy formulation
19 How do you ensure proper implementation of your strategy?
20 What is the methodology adopted by you fo r:
New Product Development
Design Development
Testing
21 How do you plan and design the manufacturing process?
22 What are your process control techniques / tools :
SPC__________
Six Sigma_________
ISO 9001:2000 QMS_________
Any Other________
23 What is the methodology adopted by you for product / process improvement?
Market Feedback_________
ISO 9001:2000 QM S________
Quality Circle________
Kaizen__________
Juran Quality Improvement________
KTPA_______
24 What are your major successful products?
Product________
Generic / Brand Name__________
Customer Needs Satisfied________
Sales INR ______MILLION
25 Do you own any patents?
Yes__________No__________
26 If yes, for which products / process?
27 How often do you survey customers?
28 Dp you have any technological collaboration?
Yes______No________
29 If yes, since__________ Years
30 What kind of collaboration?
Technological Transfer_______
Alliance______________
Licensing________
Any Other__________
31 What federal regulatory approval and/or documentation do you need?